ATHA Stock Analysis: Buy, Sell, or Hold?
ATHA - Athira Pharma, Inc. Common Stock
$6.75
-0.44 (-6.12%)
âŧ
5d:
-3.02%
30d:
+73.75%
90d:
+72.19%
WAIT
LOW Confidence
Analysis Updated: Jan 9, 2026 12:00 AM ET
Earnings: Feb 26, 2026
0d
Get Alerted When ATHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ATHA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ATHA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ATHA is currently trading at $6.75, which is considered fair based on recent price action.
Technical Outlook: Technically, ATHA is in a strong uptrend. Immediate support is located at $6.41, while resistance sits at $7.77. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $4.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATHA is in a strong uptrend. Immediate support is located at $6.41, while resistance sits at $7.77. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $4.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
38/100
(SELL)
Volume Confirmation
UNKNOWN
Confidence Score
53.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BEARISH: Downward momentum (-6.1%)
- BEARISH: Trading 40.7% above Wall St target ($4.00)
- WARNING: Composite score 38/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$6.41
Resistance Level
$7.77
Current Trend
Strong Uptrend
Technical data as of
Jan 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.34
Wall Street Target
$4.00
(-40.7%)
Share & Embed Analysis
Last updated: August 25, 2026 4:04 AM ET
Data refreshes hourly during market hours. Next update: 5:04 AM
Data refreshes hourly during market hours. Next update: 5:04 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 38 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$560 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
